



GDM-associated insulin deficiency hinders the dissociation of SERT from ERp44 and down-regulates placental 5-HT uptake.

Yicong Li, Coedy Hadden, Preeti Singh, Charles P Mercado, Pamela Murphy, Nafisa K Dajani, Curtis L Lowery, Drucilla J Roberts, Luc Maroteaux, Fusun Kilic

► To cite this version:

Yicong Li, Coedy Hadden, Preeti Singh, Charles P Mercado, Pamela Murphy, et al.. GDM-associated insulin deficiency hinders the dissociation of SERT from ERp44 and down-regulates placental 5-HT uptake.. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111 (52), pp.E5697-705. 10.1073/pnas.1416675112 . hal-01225032

HAL Id: hal-01225032

<https://hal.science/hal-01225032>

Submitted on 4 Mar 2016

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

GDM-associated insulin deficiency hinders the dissociation of SERT from ERp44 and down-regulates placental 5-HT uptake

Yicong Li¹, Coedy Hadden¹, Preeti Singh¹, Charles Mercado¹, Pamela Murphy², Nafisa K. Dajani², Curtis L. Lowery², Drucilla J. Roberts³, Luc Maroteaux⁴, and Fusun Kilic^{1*}

¹Departments of Biochemistry and Molecular Biology, and ²Obstetrics and Gynecology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA; ³MGH, Department of Pathology, Boston, Massachusetts, USA; ⁴INSERM UMR S-839, Institut du Fer a Moulin, 17 rue du Fer a Moulin, 75005 Paris, France

Submitted to Proceedings of the National Academy of Sciences of the United States of America

Serotonin (5-HT) transporter (SERT) regulates the level of 5-HT in placenta. Initially, we found that in gestational diabetes mellitus (GDM), while free plasma 5-HT levels were elevated, the 5-HT uptake rates of trophoblast were significantly down-regulated, due to impairment in the translocation of SERT molecules to the cell surface. We sought to determine the factors mediating the down-regulation of SERT in GDM-trophoblast. We previously reported that an endoplasmic reticulum chaperone, ERp44, binds to Cys200 and Cys209 residues of SERT to build a disulfide bond. Following this post-translational modification, before trafficking to the plasma membrane, SERT must be dissociated from ERp44; and this process is facilitated by insulin signaling and reversed by the insulin receptor blocker AGL2263. However, the GDM-associated defect in insulin signaling hampers the dissociation of ERp44 from SERT. Furthermore, while ERp44 constitutively occupies Cys200/Cys209 residues, one of the SERT glycosylation sites, Asp208 located between the two Cys residues, cannot undergo proper glycosylation, which plays an important role in the uptake efficiency of SERT. Herein, we show that the decrease in 5-HT uptake rates of GDM-trophoblast is the consequence of defective insulin signaling, which entraps SERT with ERp44 and impairs its glycosylation. In this regard, restoring the normal expression of SERT on the trophoblast surface may represent a novel approach to alleviating some GDM-associated complications.

serotonin | serotonin | ERp44 | ERp44 | insulin

INTRODUCTION

Gestational diabetes mellitus (GDM) affects 3% to 10% of pregnancies in developed countries and continues to be a major public health problem (1). In pregnancies complicated by GDM, the signaling of insulin is impaired so that glucose uptake or production cannot be stimulated or suppressed. Like in other forms of hyperglycemia, GDM affected maternal pancreatic β -cells do not function sufficiently to provide the physiological insulin requirement resulting in decreased insulin sensitivity (increased insulin resistance) coupled with an inadequate insulin response via impairment in the insulin signaling mechanism (2-7, 9). GDM is associated with placental pathology and various maternal and fetal complications during pregnancy, birth and later in life (2-11). The diabetic intrauterine environment results in an increased incidence of pediatric and adult complications including obesity, diabetes, and cardiovascular disease (1-7). The factors mediating these pathologies are unknown.

There is a dynamic relationship between pregnancy and serotonin (5-HT) – a multifunctional signaling molecule that plays extracerebral roles during development and throughout life. As a mitogen, 5-HT promotes cell division and mitosis regulating morphogenesis, cell proliferation, migration, differentiation and acts as a developmental signal during early embryogenesis (12-21). Preclinical studies with mouse embryos lacking the gene for tryptophan hydroxylase1 (TPH1), demonstrated the importance

of 5-HT in early embryonic development (15). The TPH-1 deficient embryos develop cardio-pulmonary dysfunction later in life, (15) as a function of the maternal genotype (21). Clinical studies found that altered 5-HT genetics results in adult-onset mental illnesses (22). Altering the levels of free 5-HT in extracellular locations also affects the development of embryo. For example: offspring of mothers who used 5-HT transporter, SERT blocker (SSRI) in the first trimester showed approximately a 2-fold higher risk for cardiac abnormalities and a 1.8-fold increased risk for other congenital malformations compared to the entire national registry population (23). Furthermore, mice lacking the gene for SERT (*SERT*^{-/-}) develop obesity, cardiovascular and neurological complications and their embryos show various developmental defects (21). Altogether, these studies emphasize the significance of normal 5-HT levels in development and pregnancy.

5-HT, a potent vasoconstrictor (24), plays a critical role in placentogenesis and embryogenesis (25-26, 28). Normal zygotic implantation involves trophoblastic invasion and colonization of the uterine spiral arteries. The resultant trophoblast-mediated remodeled vessels are converted to high capacitance slow flow channels ensuring unrestricted low pressure blood flow to the developing placenta and thus the embryo (29). Local placental elevation in plasma (free) 5-HT may cause pre-placental vasoconstriction elevating vascular resistance and increasing the local blood pressure to the placenta (26, 28). Furthermore, the impact of vasoconstriction and resultant increase in blood pressure can be lethal to the developing embryo (29). Pathologies of placental perfusion are associated with perinatal morbidity and mortality

Significance

Our findings provide insight on the molecular mechanism in which insulin regulates the dissociation of ERp44, an endoplasmic reticulum chaperone, from the serotonin (5-HT) transporter (SERT) following the completion of disulfide bond formation. Furthermore, our data show that gestational diabetes mellitus-associated defects in insulin signaling tethers SERT with ERp44, at the intracellular compartment which down-regulates 5-HT uptake rates of the placental trophoblast. All the trophoblast used in these studies were isolated and purified directly from healthy or GDM placentas in our laboratories

Reserved for Publication Footnotes

Table 1.

TABLE 1 Parameters of normal and GDM subjects

	BMI	Weight gain (lb)	Blood Glucose level (mg/dl)	Plasma 5-HT level (ng/ml blood)
Normal (n=5)	28.9 ± 24 ± 5.43	100 ± 13.44	0.59 ± 0.07	
GDM (n=5)	37.5 ± 35.7 ± 6.7	160 ± 17.00	0.78 ± 0.04	

The GDM subjects were overweight (BMI 25–29.9 kg/m²) or obese (BMI >30 kg/m²) compared with non-GDM subjects with normal weight (BMI 18.5–24.9 kg/m²)




Figure 1

Fig. 1. Isolation of trophoblast cells. The immunopurification trophoblast was documented by CK-7 (41). (A) and trophoblast protein (NDGO1) (44).




Figure 2

Fig. 2. Purification of trophoblast cells. Both normal and GDM trophoblast were stained with these Abs followed by Alexa Fluor 488 anti-mouse as secondary Ab. Negative control represents trophoblast without CK-7 stain. In normal placenta the trophoblast of 82 ± 0.91% appeared as positive and in GDM placenta 86.55 ± 5.07% of trophoblast were stained with CK7. The cell lines stained with NDGO1 appeared as 56.2 ± 1.03% positive stain and 49.7 ± 2.37% pure for GDM trophoblast.

(28). Therefore, trophoblastic SERT plays an important role by regulating the plasma (free) 5-HT levels in uteroplacental blood during pregnancy, which may prevent vasoconstriction to the




Figure 3

Fig. 3. Characterization of trophoblast cells for the 5-HT uptake rates. Trophoblast cells were isolated and purified from normal and GDM placentas (all groups, n=5). The [³H]-5-HT uptake rates were measured in intact cells (2.3 X 10⁵ per assay) (37, 39, 45). Rate of uptake is expressed as the means and SD values of triplicate determinations from three independent samples in each group. The (*) represents the results of a two-tailed Student's t-test with p < 0.001, (compared with normal trophoblast uptake rates).




Figure 4

Fig. 4. Comparison of PM SERT expression on freshly isolated trophoblast from normal and GDM placentas. (A) Trophoblast were prepared from normal (N) and GDM placentas. PM expression of SERT was determined by flow cytometry (75, 76). Mean fluorescence intensity of SERT expression in trophoblast (5 X 10⁴ per assay) isolated from normal placentas (red histogram) was higher than in trophoblast from GDM placentas (blue histogram), black histogram represents negative control. Flow cytometry revealed a decrease of 51% in the expression levels of SERT in trophoblast of GDM placentas. * statistical difference between normal and GDM trophoblast. (B) For quantification of SERT on the PM, trophoblast (1.5 X 10⁶ per biotinylation assay) cells were treated with sulfo-NHS-SS-biotin as described (37, 39, 68). The WB analysis of the biotin labeled PM proteins was performed with anti-SERT or Na⁺/K⁺-ATPase Abs (locates PM proteins). All lanes contain protein recovered from the same number of cells (1.5 X 10⁶ per assay). The band densities were calculated as the ratio of each band to the level of actin. Averaged data from three independent experiments are presented ± S.E. The values are statistically different (P<0.001, Student's t test).

placenta thereby securing a stable blood flow to the developing embryo (25-26, 28).

Our initial experiments show that plasma free 5-HT levels in GDM associated pregnancies are higher than their levels in normal pregnancies. Furthermore, the 5-HT uptake rates of trophoblast isolated from the placentas of GDM-associated preg-




Figure 5

Fig. 5. WB analysis of SERT expression in whole trophoblast cells. The whole cell expression of SERT was analyzed in trophoblast cells (1.5×10^6 per assay) isolated from normal (N) and GDM (G) placentas. SERT proteins in trophoblast cells from normal placenta appeared in one major band at 80 kD confirming the reported studies (37, 45) while it appeared from GDM placenta as two bands at 80 and 55 kD. The band densities were calculated as the ratio of each band to the level of actin. Relative SERT levels are expressed at 80 and 55 kD as the means and SD values of triplicate determinations from 4 independent experiments. All lanes contain protein recovered from the same number of trophoblast (1.5×10^6 per assay). The (*) represents the results of a two-tailed Student's t-test with both $p < 0.001$, (compared with 80 kD band of normal trophoblast).

nancies are significantly lower than the rates of control placentas. The biochemical analyses determine that the down-regulation of 5-HT uptake rates is a consequence of the decreased number of SERT molecules on the surface of trophoblast cells in GDM-placentas. Further studies find SERT bound to ERp44, an endoplasmic reticulum (ER) protein (30-32), in GDM trophoblast and that their association keeps SERT away from the PM, retaining it in the intracellular compartment.

Like other members of the Na^+ - and Cl^- - dependent monoamine transporter family, SERT has two sites for N-linked glycosylation (Asp208 and Asp217) (33-37) and two cysteine (Cys200 and Cys209) residues (38, 39) connected by a disulfide bond on the second extracellular loop. ERp44 binds to Cys200/Cys209 and facilitates the disulfide bridge formation (39). Interestingly, in the healthy placenta, insulin signaling assists the dissociation of SERT from ERp44 allowing the transporter proteins to be translocated to the PM. However, in GDM, due to defective insulin signaling, ERp44 cannot dissociate from Cys200/Cys209 on SERT. Consequently, in GDM-trophoblast, the glycolytic enzymes cannot modify the N-glycosylation sites, Asp208, which is buried between the occupied Cys200 and Cys209 on SERT. Based on these findings, we propose that in GDM, due to defective insulin signaling, SERT cannot perform proper the post-translational modifications neither can move to the PM of the trophoblasts.

RESULTS

The blood glucose, free plasma 5-HT levels, along with the other parameters as listed in Table 1 were measured in GDM and normal subjects. Following published methods (40-44), trophoblast from gestational age matched normal and GDM placentas were isolated (Fig. 1) and purified (Fig. 2). 5-HT uptake rates of trophoblast were measured in 2.3×10^5 cells per group (Fig. 3).

Under GDM conditions uptake rates of trophoblast were 33% lower than the trophoblast of normal placenta ($P < 0.01$).

The 5-HT uptake rates of GDM trophoblast cells are lower as a result of reduced surface SERT molecules. Using flow cytometry and biotinylation of surface proteins followed by WB analysis, the density of SERT molecules on the PM was determined in trophoblast cells isolated from normal and GDM placentas (Fig. 4A and B). Flow cytometry revealed a 50% decrease in SERT density (Fig. 4A) which closely mirrored the 42% decrease determined by the surface biotinylation assay (Fig. 4B). These findings indicate that the decrease in 5-HT uptake rates of GDM trophoblast is the result of a decrease in the surface density of SERT molecules. The Na^+/K^+ -ATPase and actin were measured at a similar level in both trophoblast cells, normal and GDM (Fig 4).

The total SERT expression in whole cells was analyzed to investigate the cause of down-regulation of SERT on the PM of GDM-trophoblast. WB analyses for total trophoblastic SERT were similar between normal and GDM placentas (Fig. 5). However, the pattern of the SERT proteins on the SDS-PAGE appeared different. Normal trophoblast SERT proteins were identified as one major band at 80 kD; while in GDM-trophoblast they appeared as two major bands at 80 kD and 55 kD (Fig. 5).

In an earlier study, glycosylation sites deleted, unglycosylated SERT protein was identified in the JAR cell line (human choriocarcinoma cells) at around 55 kD (37, 45). Therefore, our identified lower band of SERT was analyzed to determine if it was unglycosylated or in a differentially glycosylated form. The trophoblast cells from normal and GDM placentas were pretreated with specific glycosidase inhibitors: PNGaseF, EndoH, Tunicamycin, Castanospermin and Swainsonine (Table 2). Each inhibitor acts at a different step in glycolytic pathway. The 5-HT uptake rates of the trophoblast of a normal placenta were analyzed following the treatment of these inhibitors, individually at a range of concentrations (Fig. 6). Pretreatment with Tunicamycin at 10 – 100 $\mu\text{g}/\text{ml}$ significantly reduced the 5-HT uptake rate of trophoblast to 32 – 72% of the untreated group. The effects of castanospermin and swainsonine reduced the 5-HT uptake rates of trophoblast at the highest concentrations, 500 $\mu\text{g}/\text{ml}$ and 1 $\mu\text{g}/\text{ml}$, respectively. The difference in the 5-HT uptake rates of GDM and normal trophoblast was 33%, which is close to the rates of healthy trophoblast cells treated with 10 $\mu\text{g}/\text{ml}$ of tunicamycin. Therefore, we compared the effect of tunicamycin on the 5-HT uptake rates of trophoblast from normal and GDM-placentas following tunicamycin pretreatment (Fig. 7). At 10 $\mu\text{g}/\text{ml}$ tunicamycin, the 5-HT uptake rate of trophoblast from both normal and GDM placentas was down-regulated significantly; moreover the 5-HT uptake rate of tunicamycin treated trophoblast from the normal placenta was decreased by 30% nearly to the rate of untreated trophoblast from the GDM-placenta. Tunicamycin prevents glycosyl modification at the initial step leaving a nascent polypeptide chain (46). Overall, these findings suggest that at least one of the two N-link glycosylation sites is not fully glycosylated in GDM trophoblast.

The WB analysis of inhibitor-treated trophoblast was performed with SERT Ab (Fig. 8). The higher bands in both normal and GDM trophoblast were shifted to 55 kDa after inhibitor treatment (37), indicating that the formation of the lower band in GDM is relatively close to unglycosylated SERT. Overall, the results of WB analysis suggest that the lower molecular weight band of SERT in GDM trophoblast is similar to the PNGase F-treated normal trophoblast samples suggesting that in GDM, SERT does not complete the glycosyl modification Which is important for its correct folding and translocation to the PM (37, 39).

ERp44 enhances its coupling with SERT in GDM at the intracellular level. Recently, we reported that ERp44 binds to SERT on Cys200 and Cys209 (39) to build a disulfide bond between these

Table 2.

TABLE 2. Glycosylation Inhibitors

Inhibitor and effective sites	Expected structure	Percent decrease in 5-HT uptake rates of trophoblasts
PNase F cleaves between the innermost GlcNAc and asparagine residues from N-linked glycoproteins	Nascent SERT (No glycosylation)	
Endoglycosidase H cleaves the bond between two GlcNAc subunits, N-acetylglucosamine residue remaining on the asparagine (46).	GlcNAc- SERT	
Tunicamycin, a competitive inhibition of UDP-GlcNAc, prevents the glycosyl modification at initial step (46).	Nascent SERT (No glycosylation)	35-72.3% Significant (P value <0.001)
Castanospermine, α -glucosidase Glc ₃ Man ₉ GlcNAc ₂ -SERT inhibitor, prevents removal of the glucose residues (46).	Glc ₃ Man ₉ GlcNAc ₂ -SERT	28.7% Not Significant (P value=0.02)
Swainsonine inhibitor of Golgi mannosidase II (46).	Man ₅ GlcNAc ₂ -SERT	7.8% Not Significant (P value=1.54)




Figure 6

Fig. 6. Glycolytic enzymes inhibitors on the trophoblast cells isolated from healthy placenta. The inhibitors, Tunicamycin, castanospermin and swainsonine (46), on the glycolytic enzyme were used individually to treat the normal trophoblast followed by measuring [^3H]-5HT (2.3×10^5 intact cells per assay) (37, 39). Rate of uptake is expressed as the means and SD values of triplicate experiments. The (*) represents the results of a two-tailed Student's t-test with both $p < 0.001$, (compared with untreated trophoblast uptake rates). The effective sites on these enzymes are listed in Table 2.

two Cys residues (38). ERp44 works as a quality control check point for the immature proteins leaving from the ER (30-32). In co-IP assays, the level of association between ERp44 and SERT was tested in trophoblast from normal and GDM placentas. Interestingly, in GDM trophoblast, the amount of SERT precipitated with ERp44-Ab was 55% higher than the trophoblast from the normal placenta (Fig. 9). A similar percent level of precipitation was found when the cellular proteins were precipitated on protein A sepharose beads coated with SERT Ab and the proteins on the beads were analyzed by WB with ERp44 Ab (Fig. 9, Panel A); or *vice versa* (Fig. 9, Panel B).

Furthermore, the SERT Ab-depleted cell lysate was analyzed for the expression levels of ERp44 in normal and GDM tro-




Figure 7

Fig. 7. Impact of tunicamycin on the 5-HT uptake rates of trophoblast. The 5-HT uptake rates of intact trophoblast cells were measured following pretreatment with tunicamycin at various concentrations (44). [^3H]-5HT uptake rates were measured in intact cells (2.3×10^5 per assay) (37, 39). Rate of uptake is expressed as the means and SD values of triplicate determinations from three independent samples in each group. Asterisks indicate statistical difference between normal- and GDM-trophoblast (*); treated and untreated trophoblast (**). All assays were performed in triplicate ($n = 5$ group).

phoblast (Fig. 9C). The level of ERp44 appeared 53% higher in SERT Ab-depleted lysate of normal trophoblast cells than GDM trophoblast. This finding, in particular, completes the results of the IP assays in Figure 5A and B, and confirms that the level of ERp44 in depleted cell lysate is higher in trophoblasts of normal placenta, than in GDM placental cells because the majority of ERp44 was depleted by SERT Ab. Thus, SERT and ERp44 coupling is enhanced in GDM trophoblast compared with normal trophoblast. Since ERp44 is highly regulated via insulin signaling, we wanted to first verify if insulin signaling was damaged in GDM trophoblast.




Fig. 8. Analysis of glycosylated vs unglycosylated SERT proteins. The source of 55 kD band recognized by monoclonal SERT Ab in the trophoblast of GDM placentas was evaluated for differences in the N-glycosylation of the transporter protein (37, 39). Trophoblast (1.5×10^6 per assay) from normal (N) and GDM placentas were treated with PNGase F and EndoH. The active site of each inhibitor is listed in Table 2. PNGase F treatment brought the 80 kD band in normal and GDM trophoblast cells to the 55 kD level (37). Immunoblot analyses were done with horseradish peroxidase-conjugated streptavidin as described under "Experimental Procedures." The positions of molecular mass standards run on the same gel are shown in kilodaltons. Averaged data from three independent experiments are presented. Quantifications of the WB analysis results were performed by densitometric scanning. Both treatments produced bands lower than the one observed in GDM trophoblast. The difference is indicated with red markers on the blots.




Fig. 9. The physical association between SERT and Erp44 in trophoblast. The lysates of trophoblast (1.5×10^6 per assay) were prepared and subjected to IP in the presence (+Ab) or absence (-Ab) of monoclonal SERT Ab (A) or polyclonal Erp44 Ab (39) (B). The blots show the level of association between SERT-Erp44 elevated in GDM trophoblast. To verify these findings SERT Ab depleted lysates were analyzed for the level of unbound Erp44 in both groups (C). The band densities were calculated as the ratio of each band to the level of actin and the SERT levels are expressed as the means and SD values of triplicate determinations from 3 independent experiments. All groups, $n=5$. Averaged data from three independent experiments are presented \pm S.E. The values are statistically different ($p < 0.001$, Student's t test).

Insulin signaling is required for the dissociation of Erp44 from SERT. The phosphorylation level of insulin receptor (IR) is related to its signaling ability (47-50). The trophoblast from nor-




Fig. 10. The Phosphorylation level of IR in trophoblast. Trophoblast (1.5×10^6 per assay) were isolated from normal (N) or GDM placentas. The cell lysates were either analyzed by WB with IR or actin Abs, or prepared for IP with IR Ab coated protein A beads. The following WB analysis of IR pulled down proteins with monoclonal phosphotyrosine (pTy) Ab showed a decrease in the level of phosphorylated IR and the other phosphoproteins pulled down by receptor Ab. The band densities were calculated as the ratio of each band to the level of actin. Averaged data from three independent experiments are presented \pm S.E. The values are statistically different ($p < 0.001$, Student's t test).




Fig. 11. Effect of insulin on 5-HT system in trophoblast cells. Trophoblast were treated with insulin at various concentrations (0 - 500 nM) for 24-hr. (A) RT-PCR analyses were performed on insulin-treated trophoblast cells (2.3×10^5 per assay). SERT mRNA levels from trophoblast cells were not altered by insulin-treatment. (B) 5-HT uptake rates of trophoblast (2.3×10^5 per assay) were measured as a function of insulin treatment. (C) The level of SERT on the PM of trophoblast (1.5×10^6 per assay) isolated from normal placentas was determined by surface biotinylation technique as described under Experimental Procedures. WB analysis of the biotin labeled PM proteins was performed with anti-SERT. All lanes contain protein recovered from the same number of trophoblast cells (1.5×10^6 per assay). The band densities were calculated as the ratio of each band to the level of actin. Averaged data from three independent experiments are presented \pm S.E. The values are statistically different ($p < 0.001$, Student's t test).

mal and GDM placentas were evaluated by WB analysis with monoclonal phospho-tyrosine as primary Ab (Fig. 10). Although




Figure 12

Fig. 12. Insulin signaling mediated coupling between ERp44 and SERT. The impact of insulin signaling on dissociation of SERT from ERp44 was determined in trophoblast (1.5×10^6 per assay). The trophoblast of normal or GDM placentas were treated with 100 nM insulin (I) in the absence or presence of 5 μ M AGL2263 (52). At the end of 24 hr incubation, the cells were lysed and the detergent soluble cellular proteins were IP on monoclonal SERT Ab coated protein A sepharose beads. The SERT Ab bound proteins were analyzed by WB with polyclonal ERp44 Ab. First, the level of actin in each corresponding blot was normalized then the band densities were calculated as a ratio to the level of actin. The SERT levels are expressed as the means and SD values of triplicate determinations from 3 independent experiments. All groups, $n=5$. Averaged data from three independent experiments are presented \pm S.E. The values are statistically different ($p < 0.001$, Student's t test). Asterisks indicate statistical difference between normal- and GDM trophoblast (*); insulin pretreated and untreated normal trophoblast (**).




Figure 13

Fig. 13. Insulin signaling upregulates 5-HT uptake rates of trophoblast of normal placentas. Insulin treatment on ERp44-SERT dissociation was followed by determining the 5-HT uptake rates of trophoblast following a pretreatment with either 100 nM insulin or 5 μ M AGL2263 or with both insulin (100 nM) and AGL2263 (5 μ M). Trophoblast cells were isolated and purified from normal and GDM placentas (all groups, $n=5$). Then the [3 H]-5HT uptake rates were measured in intact cells (2.3×10^5 per assay). Rate of uptake is expressed as the means and SD values of triplicate determinations from three independent samples in each group. The values are statistically different ($p < 0.001$, Student's t test). Asterisks indicate statistical difference between normal- and GDM trophoblast (*); insulin pretreated and untreated normal trophoblast (**).

the protein expression levels of IR appeared similar in both groups, the level of phospho-tyrosine Ab binding was significantly

lower in GDM placental trophoblast than the normal placental trophoblast. These findings are consistent with reported studies that show lower insulin signaling in muscle cells of GDM (47) and in the choriocarcinoma JAR cell line (45).

Insulin signaling elevates 5-HT uptake via releasing SERT from ERp44 to the PM. As reported previously, insulin signaling regulates the ERp44-mediated maturation of adiponectin in adipocytes (51). The impact of insulin on the dissociation of ERp44 from SERT was tested in the trophoblast from normal placentas by treating them with various concentrations of insulin.

First, the experimental system for insulin treatment on trophoblast was optimized by measuring the mRNA level of SERT, the 5-HT uptake rates, and the level of SERT on the PM and in trophoblast, pretreated with various amounts of insulin (0-500 nM) for 24-hr (Fig. 11A). We found that insulin pretreatment, at any level, does not change total SERT expression at the mRNA level in trophoblast cells prepared from normal placentas ($n=5$).

Next, the 5-HT uptake rates of insulin-pretreated trophoblast cells were determined and we found a significant ($P < 0.001$) step-wise elevation in the rates compared to untreated cells (Fig. 11B). These findings were confirmed with the measurement of SERT levels on the PM of trophoblast cells following insulin treatment (Fig. 11C). The uptake rates and the surface biotinylation assays showed the most prominent effect of insulin on trophoblast 5-HT system at 100 nM as around 2-fold compared to the untreated group of cells.

Finally, the impact of insulin at 100 nM on the surface SERT expression and 5-HT uptake rates of trophoblast was studied to determine if the effect was due to the insulin treatment or through the dissociation of SERT from ERp44, and whether it could also be shown in the trophoblast of GDM placentas.

Trophoblast cells were prepared from normal or GDM placentas (Fig. 12). They were incubated in the presence of stimulants, insulin (100 nM) or both insulin and AGL2263 (AGL, 5 μ M) IR blocker (52), together for 24-hr. At the end of the incubation time, the cells were prepared for co-IP assays. The soluble cellular proteins were precipitated on SERT Ab and then eluted to analyze via WB assay using ERp44 Ab (Fig. 12). The densities of the bands were normalized with the corresponding levels of actin and plotted in a bar graph. Insulin treatment decreased the level of ERp44 on SERT-Ab in Insulin-treated normal trophoblast by 45%, while no coupling difference was observed under GDM. In the meantime, blocking partially IR reversed insulin-mediated SERT release in normal but not GDM, suggesting the insulin signaling-dependent dissociation of ERp44 from SERT.

The co-IP data shows that insulin signaling elevates the dissociation rate of SERT from ERp44 in trophoblast cells of normal placentas. We confirmed that insulin treatment up-regulates 5-HT uptake rates of trophoblast by reversing the increased uptake with an IR blocker (Fig. 13). Furthermore, insulin treatment of GDM trophoblast does not facilitate the dissociation of ERp44 from SERT nor does it elevate the PM level of SERT.

DISCUSSION

Peripheral 5-HT is synthesized by the intestinal enterochromaffin cells and secreted into blood (53), where the free plasma level is tightly regulated by a saturable re-uptake mechanism of SERT on the PM of platelets and several tissues. SERT cDNA's have been cloned and sequenced from a number of sources, including human placenta (54-56), platelets (57, 58), brain (59), pulmonary endothelial cells (60), enterocytes (61), and liver (62). SERT is encoded by a single copy gene (SLC6A4) for all tissues with tissue specific alternative promoters (63). We investigate the control of trophoblastic SERT on the PM of the maternal facing brush border (54, 55), isolated from GDM and normal placentas and how it may regulate free 5-HT in the placental blood.

In platelets, the role of the SERT is to take up 5-HT from the circulation and accumulate it inside; from there, 5-HT is taken up by the dense granule-located vesicular monoamine transporter (VMAT) and packed in the dense granule. This effect is systemic. In contrast, the role of SERT in the trophoblast has not yet been established, despite the fact that this tissue expresses very high levels of the transporter (54). We suggest that local control of 5-HT levels in the placental vascular bed is critical during pregnancy and that trophoblastic uptake of 5-HT by SERT is the critical mechanism of its local (placental) regulation. 5-HT is a potent vasoconstrictor and the placenta requires high capacitance, low pressure perfusion. SERT regulation of local plasma 5-HT levels in placental vessels has a protective role preventing 5-HT driven vasoconstriction in the pre-placental vascular bed, thereby securing a stable blood flow to the fetus. Trophoblast line the uterine spiral arteries in early implantation, remodeling the vessels to high capacitance slow flow channels. This suggests that local control of pre-placental blood flow is important. Evidence that 5-HT levels play a role in regulation of maternal blood flow to the placenta is found in the pathologic condition of pre-eclampsia. In pre-eclampsia altered placental blood flow (local hypertension) results in complications including fetal growth restriction due to significant flow related placental pathology (infarcts, distal villous hypoplasia, and abruption) (26-28). Elevation in free/unbound 5-HT in blood plasma causes pre-placental vasoconstriction elevating vascular resistance and exacerbating the local blood pressure to the placenta. Indeed 5-HT concentration in pre-eclamptic pregnancy is significantly higher than in normal pregnant women (28) suggesting that 5-HT regulation is altered in this pregnancy specific pathology. Therefore, trophoblastic SERT clearance of 5-HT may be a critical player in the maintenance of uteroplacental blood flow during pregnancy (25). The fate of 5-HT after uptake by the trophoblast cells is not well established. However, in neuronal cells and platelets, free/unbound 5-HT in cytosol either binds to the proteins (57), or is degraded by the monoaminooxidase (MAO) system (53), or is stored and then released to the fetal circulation to provide the embryo with 5-HT needed in early embryogenesis (12, 64, 65).

There is a dynamic relationship between pregnancy, 5-HT, and glucose metabolism (18-20, 66). Clinical studies show that the free 5-HT concentration in blood is significantly higher in type 2 diabetes than healthy/control groups (20) and is elevated by 15.6% in pregnancy (67). In an *in vitro* model of diabetes, extracellular glucose levels were correlated with the 5-HT uptake rates of the JAR cells (45). Our data showed an elevation in the blood plasma, free 5-HT level in GDM.

Following the successful isolation and purification of trophoblast cells from healthy (normal) and GDM-associated placentas, the 5-HT uptake rates of trophoblast we show herein to be 33% lower than in normal placentas. This finding was correlated with lower SERT density on the PM of GDM-trophoblast: FACS analysis together with surface biotinylation followed by WB analysis showed that the density of SERT was 42% less on the surface of GDM-trophoblast than normal-trophoblast. These data imply that SERT molecules are held at intracellular compartments in GDM-trophoblast more than in normal trophoblast. These findings suggest that SERT is arrested in the ER of GDM-trophoblast. Earlier studies identified the association of SERT with an ER protein, ERp44, during the disulfide bond formation between Cys200 and Cys209. In testing the binding ability between SERT and ERp44, our co-IP data indicated an enhanced association in GDM-trophoblast. Other studies have reported a role for insulin signaling in ERp44 dissociation (51). Interestingly, surface SERT levels and 5-HT uptake rates by trophoblast cells from normal placentas significantly rose as plasma insulin levels increased. However, insulin signaling, as represented by the level

of IR phosphorylation, was 4-fold lower in GDM- than normal-trophoblast.

In general, proper post-translational modifications are essential regulatory factors for membrane trafficking and the neurotransmitter uptake functions of SERT (37, 39, 68), NET (69) and DAT (70, 71). A modification such as *N*-glycosylation has an important role in the quality control pathway that ensures correct folding and processing of membrane proteins (71, 72). Defects in the glycosylation (37), oligomerization (68) or disulfide bond formation (39) processes retain SERT in the ER, similarly to other proteins (30-32, 73, 74). Despite a wealth of knowledge on the protein mediators and quality control checkpoints in SERT maturation there is limited information connecting this to human diseases.

Our studies showed that free thiol at the 2nd external loop in SERT protein structure is sufficient for the intracellular retention of SERT, but SERT mutants without Cys residues on the second extracellular loop are able to reach the PM despite the lack of a disulfide bond (38). These studies suggest a quality control mechanism involved in SERT maturation, which recognizes exposed Cys in SERT molecules and retains them intracellularly. The ability of Cys mutants of SERT to reach the PM further implies the quality control mechanism does not recognize non-native structures such as hydrophobic patches or immature glycans, but rather, the retention of Cys mutants of SERT is entirely thiol-dependent. SERT has two N-glycosylation sites, Asn208 and Asn217 but ERp44 binds to Cys200 and Cys209. One of the glycosylation sites on SERT is between the two Cys residues where ERp44 binds. Based on these findings, we propose that the differential glycosylation of SERT in GDM-trophoblast could be a result of ERp44-retained process; while the two Cys residues are occupied by ERp44 the Asn208 site cannot be modified by the glycolytic enzymes. ERp44-SERT coupling affects the glycosylation pattern of SERT.

Therefore, the glycan patterns of SERT in GDM- and normal-trophoblast were found to be significantly different; where in GDM 37% of the expressed SERT is fully glycosylated and 63% has immature glycans. These findings parallel the 5-HT uptake rates and the surface density of SERT in GDM-trophoblast. Furthermore, as reported earlier, in JAR cells the immature glycosylated form of SERT appeared at the same level with the lower molecular weight band of SERT in GDM-trophoblast. SERT in GDM-trophoblast was modified with immature glycans, and could not dissociate from ERp44. Thus, we hypothesize that the maturation of SERT proteins and in turn the 5-HT re-uptake/efflux function is hindered by impaired insulin signaling conditions such as GDM-associated pregnancy. In fact, as reported in *in vitro* system, if insulin was supplemented, the PM level and the 5-HT uptake rates could be restored in JAR cells pretreated with glucose at diabetic-like concentrations (45). The new findings with normal- and GDM-trophoblast nicely complete the earlier data by showing that insulin signaling plays a key role in regulating the chaperone activity of ERp44 and its dissociation from SERT; although, insulin signaling does not increase total transcription or translation of SERT.

Methods

Subjects Placentas from subjects 18 years old or older were recruited for this study (Table 1). Our study was carried out after approval from University of Arkansas for Medical Sciences (UAMS) IRB, which included these procedures, and for which subjects had previously provided written informed consent. The health conditions of subjects were followed by their physicians (Table 1). Inclusion and exclusion criteria were evaluated by review of medical history, interviewing the subject, and/or results of routine tests performed for the purpose of clinical care. We recruited term placentas from euglycemic (normal) (n=5) or GDM (n=5) affected pregnancies.

Quantitative measurement of 5HT levels by enzyme-linked immunosorbent assay Using competitive enzyme-linked immunosorbent assay (ELISA), by following the manufacturer's instructions (IBL Immuno-Biological Laboratories, Hamburg, Germany) (77). Samples are detected at 405 nM absorbance

by using ELISA plate reader (Molecular Devices Union City, CA, USA). The 5-HT (free) levels were measured in the plasma of maternal blood drawn from healthy and GDM subjects (each group n=5) (Table 1).

Isolation and purification of Trophoblast cells The trophoblast cells from the placentas were isolated and then purified by following the published methods (40-44). Placentas were placed in sterile trays, maternal side facing up. One cotyledon at a time was dissected using sharp, fine point scissors and blunt forceps. First the basal plate tissue was removed, and 30-40 g of villous tissue collected, avoiding fibrous tissue and vessels. After rinsing the tissue several times with sterile 0.9% NaCl supplemented with 100 units/ml penicillin, and 100 µg/ml streptomycin; all the blood clots were removed and the tissue was minced finely with scissors.

Next, using buffers containing DNase, Dispase and Trypsin with the Pen-Strp-Neomycin antibiotics in CMF Hank's (Ca-Mg free Hank's with 25mM Hepes, Sigma 14185) the cells were dissociated in 3 stages. Following dissociation, cells were purified on Percoll gradients 70%-5% with centrifugation at 1,200 X g for 20 minutes. The layer of trophoblast cells appears at 40%-50% gradient in 25-10ml volume with a density of 1.050-1.060g/ml. Trophoblast collections were incubated with fetal calf serum to avoid cell damage. The cell viability was determined by trypan blue dye exclusion. Our average yield was between 1.5 and 3X10⁸ cells per 40g tissue at greater than 80% viability.

Next, for the immunopurification the cells were suspended in buffer containing human HLA class I ABC antibody (Ab) W6/32 incubated with Dynabeads previously coated with goat anti-mouse IgG. At the end of incubation, the supernatant containing purified trophoblast was transferred to tubes with supplemental cytotrophoblast culture medium and centrifuged. The pellets were resuspended in the same medium. Purity of villous trophoblast was determined by cytokeratin-7 (CK-7) Ab (Fig. 1) (43) and trophoblast protein (NDGO1) (Fig. 2) (44).

Insulin and AGL2263 blocker treatment Human insulin solution is supplied by sigma 19278 (10 mg/ml stock). Insulin concentration used in this study ranged from 10nM to 500 nM, as previously published for JAR cells (45). IR blocker AGL2263 obtained from Santa Cruz Biotech (Santa Cruz, CA) was used at a concentration of 5µM as recommended (52).

5-HT uptake assay Trophoblast (2.3 X 10⁵ cells per transport assay) were initially washed with PBS solution containing 0.1 mM CaCl₂ and 1mM MgCl₂. The intact cells were quickly incubated with 14.6 nM ³H-5-HT at room temperature (RT) for 10 min. Whatman GF/B filters collected the cells after incubation, and excess solution was filtrated through a funnel. The uptake assay was stopped by washing twice with ice-cold PBS solution. The sample containing filters were placed into scintillation vials for counting. 2ß-carbomethoxy-3 trophane (ß-CIT) (Chemical Synthesis Service, NIMH) was used as negative control background (37).

Immunoprecipitation (IP) and Western blot (WB) analysis Trophoblast (1.5 X 10⁶ cells per IP assay) were lysed in IP buffer (55 mM triethylamine (pH 7.5), 111 mM NaCl, 2.2 mM EDTA, 0.44% SDS, 1% Triton X-100) supplemented with 1 mM phenylmethylsulfonyl fluoride (PMSF), and protease inhibitor mixture (PIM) as previously described (37, 39). Initially, cell lysate was incubated with protein A sepharose beads to eliminate non-specific interaction (preclear). Anti-SERT monoclonal (Mab technology, Stone Mountain, GA) Ab, anti-ERp44 polyclonal Ab (cell signaling) or anti-IR Ab (Santa Cruz Biotech, Santa Cruz, CA) was conjugated to protein A bead for 2 hours prior to incubating together with pre-cleared cell lysate overnight at 4 degrees.

WB analysis was done the next day using anti-ERp44 polyclonal Ab (Cell Signaling, Danvers, MA) (diluted 1:1000), monoclonal anti-SERT, or monoclonal Phospho-tyrosine for primary Ab (eBioscience, S.Diego, CA). Horseradish peroxidase (HRP) conjugated anti-rabbit or anti-mouse was used as the secondary Ab. VersaDoc 1000 gel visualization and analysis system was applied to analysis of densitometry of individual bands.

Glycolytic enzymes' inhibitors treatment. Trophoblast (1.5 X 10⁶ cells for glycolytic enzyme inhibitors' treatment) were first lysed in IP buffer

supplemented with PIM/PMSF (27). Protein concentration was determined under nanodrop 2000 instrument (Thermo Scientific, Wilmington, DE). Glycoproteins were denatured at 100 C for 10mins first then combined with 10G7 buffers, NP-40 and 2,000U of PNGase F solution (New England Biolabs, Ipswich, MA) for incubation at 37 C. The reaction mixture was separated by SDS-PAGE, and WB analysis was performed using SERT Ab following the ECL blotting system.

Cell surface biotinylation The trophoblast surface protein expression (1.5 X 10⁶ cells per biotinylation assay) was detected after treatment of the cells with membrane-impermeant NHS-SS-biotin as described previously (37, 39). Briefly, upon the biotinylation reaction, the cells were treated with 100 mM glycine to quench unreacted NHS-SS-biotin and lysed in tris buffer 1% SDS, 1% TX100, and PIM/PMSF. The biotinylated proteins were recovered with an excess of streptavidin-agarose beads during overnight incubation. Biotinylated proteins were eluted in sample buffer, resolved by SDS-PAGE and transferred to nitrocellulose, and were detected with the SERT Ab as described (37, 39).

Flow cytometry The level of SERT proteins on the PM of trophoblast (5 X 10⁴ cells per assay) was determined using a specific Ab (76) designed by our group and generated by Proteintech Group, Inc. (Chicago, IL) against a synthetic peptide corresponding to the second extracellular loop of SERT. This portion of the protein is not affected by the post-translational modifications of SERT such as glycosylation, disulfide bond formation, and thus, should recognize SERT in trophoblast isolated from normal and GDM placentas.

CK7 was applied to stain the intracellular compartment of purified trophoblast cells. Briefly, cells were washed with PBS and fixed with 4% formaldehyde for 20 mins, and then permeabilized with 0.1% Tx-100/PBS for 15 min at RT. After washing, cells were blocked with 0.5% bovine serum albumin for 1 hour. Then, they were then incubated with CK7 (Novus Biological) primary monoclonal Ab for 1 hr and Alexa Fluor 488 goat anti-mouse secondary Ab for additional hour at RT (75, 76).

Extracellular staining was performed to confirm trophoblast identity by using NDOG1 (trophoblast cell protein) (ThermoFisher Scientific, Waltham, MA). Cells were directly blocked with bovine serum albumin without a permeabilizing step, then washed and incubated with NDOG1 polyclonal Ab or SERT Ab on trophoblast PM for 1 hour and then incubated with secondary Ab, FITC conjugated goat anti-rabbit IgG (41-44). All flow cytometry experiments were performed in the UAMS Flow Cytometry Core Facility.

Data analysis Nonlinear regression fits of experimental and calculated data were performed with Origin, which uses the Marquardt-Levenberg nonlinear least squares curve fitting algorithm. Each figure shows a representative experiment that was performed at least three times. Data with error bars represent the means ± SD for triplicate samples. Data were analyzed by ANOVA (analysis of variance) to compare data sets and two-sided t-tests based on the ANOVA mean squared error.

ACKNOWLEDGEMENTS .

We gratefully acknowledge the UAMS Flow Cytometry Core, and thank Ms. Amber Ward for assistance in obtaining consents from subjects and providing us the samples. LM's work was supported by funds from the Centre National de la Recherche Scientifique, the Institut National de la Santé et de la Recherche Médicale, the Université Pierre et Marie Curie, and by grants from the Fondation de France, the Fondation pour la Recherche Médicale "Equipe FRM DEQ2014039529", the French Ministry of Research (Agence Nationale pour la Recherche) ANR-12-BSV1-0015-01 and the *Investissements d'Avenir* program managed by the ANR under reference ANR-11-IDEX-0004-02. This work was supported by the NIH Child Health and Human Development HD058697, and HD053477 grants and Heart Lung and Blood Institute HL091196, American Heart Association [13GRNT17240014] and the Minnie Merrill Sturgis Diabetes Research Fund, and the Sturgis Charitable Trust to FK.

- Centers for Disease Control and Prevention, (2011) National Diabetes Fact Sheet, <http://www.cdc.gov/diabetes/pubs/estimates11.htm>
- Metzger BE. et al. (2007) Summary and recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus. *Diabetes Care* 30(Suppl. 2):S251-S260
- Buchanan TA. et al. (2007) What is gestational diabetes? *Diabetes Care* 30 Suppl 2:S105-11.
- Catalano PM. et al. (2003) Gestational diabetes and insulin resistance: role in short- and long-term implications for mother and fetus. *J. Nutr.* 133(5 Suppl 2):1674S-1683S.
- Kim C. et al. (2002). Gestational diabetes and the incidence of type 2 diabetes: a systematic review. *Diabetes Care.* 25:1862-1868.
- Yamashita H. et al. (2000). Physiologic and Molecular alterations in Carbohydrate Metabolism During Pregnancy and Gestational Diabetes Mellitus. *Clinical Obstetrics and Gynecology* 43: 87-98.
- Catalano PM. et al. (1993). Carbohydrate metabolism during pregnancy in control subjects and women with gestational diabetes. *Am J Physiol* 264: E60-E67
- Vrachnis N. et al. (2012). Impact of maternal diabetes on epigenetic modifications leading to diseases in the offspring. *Exp Diabetes Res.* 2012: 538474
- Colomiere M. et al. (2009). Defective insulin signaling in placenta from pregnancies complicated by gestational diabetes mellitus. *European Journal of Endocrinology* 160: 567-578.
- Bentley-Lewis et al., Placental histomorphometry in gestational diabetes mellitus: the rela-

- tionship between subsequent type 2 diabetes mellitus and race/ethnicity. *Am J Clin Pathol.* 2014 141:587-592.
- Balsells M., et al. Major congenital malformations in women with gestational diabetes mellitus: a systematic review and meta-analysis. *Diabetes Metab Res Rev.* 28, 252-257 (2012).
- Liu et al., (1987) Prenatal development of serotonin binding protein in relation to other transmitter-related characteristics of central serotonergic neurons. *Brain Res.* 429:31-41
- Lauder J. et al. (1998). Serotonin and morphogenesis. Sites of serotonin uptake and binding protein immunoreactivity in the midgestation mouse embryo. *Development* 102: 709- 720
- Lauder J. M. (1993). Neurotransmitters as growth regulatory signals: role of receptors and second messengers. *Trends Neurosci.* 16: 233-240.
- Côté F. et al. (2003). Disruption of the nonneuronal tph1 gene demonstrates the importance of peripheral serotonin in cardiac function. *Proc Natl Acad Sci U S A.* 100: 13525-13530
- J.L.R. Rubenstein. (1998). Development of Serotonergic Neurons and Their Projections. *Biol Psychiatry* 44:145-150.
- Bonnin A. et al. (2011). A transient placenta source of 5-HT for the fetal forebrain. *Nature* 472: 347-350.
- Kim H. et al. (2010). Serotonin regulates pancreatic beta cell mass during pregnancy. *Nat Med.* 16: 804-808.
- Paulmann N. et al. (2009). Intracellular serotonin modulates insulin secretion from pancreatic beta-cells by protein serotonylation. *PLoS Biol.* 7: e1000229

1089 20. Barradas MA. et al., (1988). Intraplatelet serotonin in patients with diabetes mellitus and
1090 peripheral vascular disease. *Eur J Clin Invest.* 18 :399-404.
1091 21. Côté F. et al. (2007). Maternal serotonin is crucial for murine embryonic development. *Proc*
1092 *Natl Acad Sci U S A.* 104: 329-334.
1093 22. Taylor SE. et al. (2006). Early family environment, current adversity, the serotonin transporter
1094 promoter polymorphism, and depressive symptomatology. *Biol Psychiatry.* 60: 671-676.
1095 23. FDA Drug Safety Communication (2011) Selective serotonin reuptake inhibitor (SSRI)
1096 antidepressant use during pregnancy and reports of a rare heart and lung condition in
1097 newborn babies. Available at <http://www.fda.gov/Drugs/DrugSafety/ucm283375.htm>.
1098 24. Rapport et al., (1948). Serum vasoconstrictor, serotonin; isolation and characterization. *J.*
1099 *Biol. Chem.* 176:1243–1251.
1100 25. Ganapathy & Leibach, (1994) Human placenta: a direct target for cocaine action. *Placenta.*
1101 15:785-795.
1102 26. Filshie, G. M., et al., (1992) Urinary 5-hydroxyindole acetate concentration in pregnancy
1103 induced hypertension. *Br. Med. J.* 304: 122.
1104 27. Redline et al., (2004). Maternal vascular underperfusion: nosology and reproducibility of
1105 placental reaction patterns. *Pediatr Dev Pathol.* 7:237
1106 28. Middelkoop et al., (1993) Platelet-poor plasma serotonin in normal and preeclamptic preg-
1107 nancy. *Clin. Chem.* 39:1675-1678.
1108 29. Red-Horse et al., (2004). Trophoblast differentiation during embryo implantation and for-
1109 mation of the maternal-fetal interface. *J Clin Invest* 114:744-754
1110 30. Anelli A. and Sitia, R. (2008). Protein Quality Control in the Early Secretory Pathway. *EMBO*
1111 *J* 27: 315-327.
1112 31. Anelli et al. (2003). Thiol-mediated protein retention in the endoplasmic reticulum: the role
1113 of ERp44. *EMBO J.* 22: 5015–5022.
1114 32. Anelli et al. (2007). Sequential steps and checkpoints in the early exocytic compartment
1115 during secretory IgM biogenesis. *EMBO J.* 26: 4177–4188.
1116 33. Gielen, W., and Viehofer, B. (1974) The effect of neuraminidase on the 5-hydroxytryptamine
1117 uptake of human platelets. *Experientia (Basel)* 30, 1177–1178
1118 34. Dette, G. A., and Wesemann, W. (1979) The role of sialic acid in 5-HT binding to synaptic
1119 membranes. *Experientia (Basel)* 35, 1152–1153
1120 35. Szabados, L., (1975) Effect of 5-hydroxytryptamine on the potassium ion exchange of human
1121 platelets enriched in sialic acid. *Biochem. J.* 148, 335–336.
1122 36. Launay et al., (1992) One-step purification of the serotonin transporter located at the human
1123 platelet plasma membrane. *J. Biol. Chem.* 267, 11344–11351.
1124 37. Ozaslan, D. et al. (2003). Glycosyl Modification Facilitates Homo- and Hetero-O-
1125 ligomerization of Serotonin Transporter. A Specific Role for the Sialic Acid Residues. *J. Biol.*
1126 *Chem.* 278: 43991-44000.
1127 38. Chen et al., (1997) External cysteine residues in the serotonin transporter. *Biochemistry* 36,
1128 1479–1486
1129 39. Freyaldenhoven, S. et al. (2012). The Role of ERp44 on the Maturation of Serotonin
1130 Transporter proteins. *J. Biol. Chem.* 287:17801–17811.
1131 40. Kliman H. et al. (1986). Purification, characterization, and in vitro differentiation of cytotro-
1132 phoblast from human term placenta. *Endocrinology* 118: 1567–1582.
1133 41. Manoussaka MS. et al. (2005). Flow cytometric characterisation of cells of differing densities
1134 isolated from human term placenta and enrichment of villous trophoblast cells. *Placenta* 26:
1135 308–318.
1136 42. Clover LM. et al. (2000). A three colour flow cytometry technique for measuring trophoblast
1137 intracellular antigens: the relative expression of TAP1 in human cytotrophoblast and decidual
1138 cells. *Placenta* 21: 743–753.
1139 43. Maldonado-Estrada J. et al. (2004). Evaluation of Cytokeratin 7 as an accurate intracellular
1140 marker with which to assess the purity of human placental villous trophoblast cells by flow
1141 cytometry. *J Immunol Methods.* 286: 21-34.
1142 44. Bulmer JN. et al. (1984). Immunohistologic identification of trophoblast populations in early
1143 human pregnancy with the use of monoclonal antibodies. *Am J Obstet Gynecol* 148: 19-26.
1144 45. Unal R. et al. (2007). At diabetes-like concentration, glucose down-regulates the placental
1145 serotonin transport system by abolishing its homo-oligomerization. *J. Neurochem.* 101: 937-
1146 948.
1147 46. Elbein AD. (1991). Glycosidase inhibitors: inhibitors of N-linked oligosaccharide processing.
1148 *FASEB J.* 15:3055-3063.
1149 47. Luo J. et al. (2005). The p85 regulatory subunit of phosphoinositide 3-kinase down-regulates
1150 IRS-1 signaling via the formation of a sequestration complex. *J. Cell Biol.* 170:455–464.
1151 48. Avruch, J. (1998). Insulin signal transduction through protein kinase cascades. *Mol. Cell*
1152 *Biochem.* 182: 31–48.
1153 49. Barbour LA. et al. (2010). Chronically Increased S6K1 and IRS1 serine phosphorylation

are associated with skeletal muscle insulin resistance in GDM women with impaired glucose
tolerance postpartum. *J Clinical Endocrinology & Metabolism.* 96: 1431-1441.
50. Boileau P. et al. (2001). Dissociation between Insulin-Mediated Signaling Pathways and
Biological Effects in Placental Cells: Role of Protein Kinase B and MAPK Phosphorylation.
Endocrinology. 142: 3974–3979.
51. Wang Z.V. et al. (2007). Secretion of the adipocyte-specific secretory protein adiponectin
critically depends on thiol-mediated protein retention. *Mol. Cell Biol.* 27: 3716–3731.
52. Seale. A. et al. (2006). Vanadium and insulin increase adiponectin production in 3T3-L1
adipocytes. *Pharmacological Research* 54: 30–38.
53. Tamir H. and Gershon, MD. (1990). Serotonin-storing secretory vesicles. *Ann N Y Acad Sci.*
600: 53-66.
54. Balkovetz DF. et al. (1989). Evidence for an imipramine-sensitive serotonin transporter in
human placental brush-border membranes. *J Biol Chem.* 264: 2195-2198.
55. Padbury JF. et al. (1997). Placental biogenic amine transporters: cloning and expression. *Brain*
Res Mol Brain Res. 45: 163-168.
56. Ramamoorthy et al. (1993) Regulation of the human serotonin transporter: cholera toxin-
induced stimulation of serotonin uptake in human placental choriocarcinoma cells is accom-
panied by increased serotonin transporter mRNA levels and serotonin transporter-specific
ligand binding. *J Biol Chem* 268:21626-21631.
57. Tamir H, Kupsky WJ, Huang YL, Gershon MD. (1983). Serotonin-binding glycoprotein of
rat platelets. *J Cell Sci.* 1983 Jul;62:439-58.
58. Lesch et al., (1993) Primary structure of the human platelet serotonin uptake site: identity
with the brain serotonin transporter. *J. Neurochem.* 60:2319-2322.
59. Lesch et al., (1993) Isolation of a cDNA encoding the human brain serotonin transporter. *J*
Neural Transm 91: 67- 73
60. Bhat GB and Block ER. (1990). Hypoxia directly increases serotonin transport by porcine
pulmonary artery endothelial cell plasma membrane vesicles. *Am J Respir Cell Mol Biol.*
4:363-7.
61. Wade et al. (1996). Localization and function of a 5-HT transporter in crypt epithelia of the
gastrointestinal tract. *J Neurosci.* 16:2352–2364.
62. Chen et al., (2012). Reduced Serotonin Reuptake Transporter (SERT) Function Causes Insulin
Resistance and Hepatic Steatosis Independent of Food Intake. *PLoS One.* 7(3):e32511.
63. Bradley CC., and Blakely, RD. (1997). "Alternative Splicing of the Human Serotonin
Transporter Gene." *J. Neurochem.* 69, 1356-1367.
64. Noorlander et al. (2008). Modulation of serotonin transporter function during fetal develop-
ment causes dilated heart cardiomyopathy and lifelong behavioral abnormalities. *PLoS ONE*
3: e2782
65. Mekonto-Dessap et al., (2006). Deficiency of the 5-hydroxytryptamine transporter gene
leads to cardiac fibrosis and valvulopathy in mice. *Circulation* 113:81-89.
66. Viau M. et al. (2009). Expression of placental serotonin transporter and 5-HT2A receptor in
normal and gestational diabetes mellitus pregnancies. *Reprod Biomed Online.* 19: 207-215.
67. Gall et al., (2011). Platelet serotonin concentration at term pregnancy and after birth:
physiologic values for Croatian population. *Coll Antropol.* 35(3):715-8.
68. Kilic, F., and Rudnick, G. (2000). Oligomerization of the Serotonin Transporter and its
Functional Consequences. *Proc Natl Acad Sci U S A.* 97: 3106-3111.
69. Nguyen TT and Amara SG. (1996). N-linked oligosaccharides are required for cell surface
expression of the norepinephrine transporter but do not influence substrate or inhibitor
recognition. *J. Neurochem.* 67: 645-655.28.
70. Chen R et al. (2007). Direct evidence that two cysteines in the dopamine transporter form a
disulfide bond. *Mol Cell Biochem.* 298: 41-48.
71. Torres GE et al. (2003). Oligomerization and Trafficking of the Human Dopamine Trans-
porter. *J Biol Chem* 278: 2731-2739.
72. Hurlley S., and Helenius, A. (1989). Protein oligomerization in the endoplasmic reticulum.
Annu. Rev. Cell Biol. 5: 277–307.
73. Braakman I. et al., (1991). Folding of influenza hemagglutinin in the endoplasmic reticulum.
J. Cell Biol. 114: 401-411.
74. Klausner R. (1989). Architectural editing: determining the fate of newly synthesized mem-
brane proteins. *The New Biologist* 1: 3–8.
75. Mercado CP. et al. (2013). A serotonin-induced N-glycan switch regulates platelet aggrega-
tion. *Sci. Rep* 3: 2795.
76. Ziu, E. et al. (2012). Down-regulation of the Serotonin Transporter in hyperreactive platelets
counteracts the pro-thrombotic effect of serotonin. *J. Mol. Cell. Cardiology* 52:1112-1121.
77. Brenner B. et al. (2007). Plasma serotonin level and the platelet serotonin transporter. *J.*
Neurochem. 102: 206-216.

1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224